Publicaciones en colaboración con investigadores/as de Hospital Universitario Virgen de la Victoria (16)

2024

  1. Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 2, pp. 192-204

  2. Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial

    Lung Cancer, Vol. 189

  3. Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases

    Lung Cancer, Vol. 188

  4. The role of sex and gender in the diagnosis and treatment of lung cancer: the 6th ICAPEM Annual Symposium

    Clinical and Translational Oncology, Vol. 26, Núm. 2, pp. 352-362

2022

  1. Emerging immune checkpoint inhibitors for the treatment of non-small cell lung cancer

    Expert Opinion on Emerging Drugs, Vol. 27, Núm. 3, pp. 289-300

2021

  1. LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology

    Cancer Medicine, Vol. 10, Núm. 17, pp. 5878-5888

2020

  1. Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus

    Clinical and Translational Oncology, Vol. 22, Núm. 5, pp. 759-771

2017

  1. A consensus statement on the gender perspective in lung cancer

    Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 527-535

  2. Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy

    Clinical and Translational Oncology, Vol. 19, Núm. 2, pp. 219-226

2014

  1. MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer

    BMC Cancer, Vol. 14, Núm. 1

2013

  1. Erratum: The role of pharmacogenomics in metastatic renal cell carcinoma (Cancer and Metastasis Reviews (2012) 31:SUPPL. 1 (S29-S32) DOI: 10.1007/s10555-012-9356-x)

    Cancer and Metastasis Reviews

2012

  1. Recommendations for the optimal management of early and advanced urothelial carcinoma

    Cancer Treatment Reviews, Vol. 38, Núm. 5, pp. 431-441

  2. The role of pharmacogenomics in metastatic renal cell carcinoma

    Cancer and Metastasis Reviews, Vol. 31, pp. S29-S32

2010

  1. Treatment of cancer with oral drugs: A position statement by the Spanish Society of Medical Oncology (SEOM)

    Annals of Oncology

2009

  1. Phase II study of weekly Kahalalide F in patients with advanced malignant melanoma

    European Journal of Cancer, Vol. 45, Núm. 5, pp. 732-735

  2. SEOM guidelines for the management of non-small-cell lung cancer (NSCLC)

    Clinical and Translational Oncology